Multiple Myeloma Consortium Will Focus On Target Validation, Clinical Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The consortium will link four centers of excellence to help speed the development of new treatments for multiple myeloma. The coalition expects to begin tissue accrual within two months; a data bank will integrate laboratory and clinical data.
You may also be interested in...
Genta Targeting Year-End Genasense NDA In Myeloma Or Lymphocytic Leukemia
The NDA will be based on either a 224-patient myeloma study or a 241-patient CLL study. Genta says that it has received helpful feedback from FDA since withdrawing a Genasense NDA for melanoma.
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.
Nebivolol Approval Could Come In Mid-2007, Forest Says
The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.